Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
Authors
Braun, M SAdab, Fawzi
Bradley, C
McAdam, K
Thomas, G
Wadd, N J
Rea, D
Philips, R
Twelves, C
Bozzino, J
MacMillan, C
Saunders, Mark P
Counsell, R
Anderson, Heather
McDonald, A
Stewart, J
Robinson, A
Davies, S
Richards, F J
Seymour, M T
Affiliation
Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.Issue Date
2003-10-06
Metadata
Show full item recordAbstract
We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.Citation
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003, 89 (7):1155-8 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6601237PubMed ID
14520437Type
ArticleLanguage
enISSN
0007-0920ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6601237